Stay updated on Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page
- Check3 days agoChange DetectedThe page now shows revision v3.6.6, replacing the previous v3.6.5. This appears to be a minor backend/CMS patch with no changes to study content or patient-facing information.SummaryDifference0.0%

- Check10 days agoChange DetectedNIH grant/contract funding lines for 2019 and 2023 were added to the study record to reflect the funding sources.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision: v3.6.5 has been added to the page as a new version identifier. The Plain Language Summary and Revision: v3.6.4 have been removed, indicating a small administrative update to the study documentation.SummaryDifference0.1%

- Check31 days agoChange DetectedThe page shows updated and removed date entries (e.g., 2026-07-30, 2026-08-21, 2026-07-28, 2026-07) indicating maintenance timestamps rather than changes to the study content.SummaryDifference0.2%

- Check45 days agoChange DetectedThe page's revision label changed from v3.6.3 to v3.6.4 in the history, signaling a new build or update of the page. This reflects deployment/maintenance activity rather than changes to the study details.SummaryDifference0.0%

- Check67 days agoChange DetectedRevision updated from v3.6.0 to v3.6.3 on the study entry, representing a minor metadata update to the ClinicalTrials.gov record. It does not alter study details, eligibility, locations, or results.SummaryDifference0.0%

Stay in the know with updates to Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page.